Celldex Therapeutics (CLDX) Expected to Announce Earnings on Thursday

Celldex Therapeutics (NASDAQ:CLDX) is expected to be releasing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Celldex Therapeutics to post earnings of ($1.00) per share and revenue of $1.5330 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, February 23, 2026 at 4:00 PM ET.

Celldex Therapeutics Stock Up 0.3%

Celldex Therapeutics stock opened at $23.00 on Thursday. Celldex Therapeutics has a 52 week low of $14.40 and a 52 week high of $30.50. The business has a 50-day simple moving average of $25.68 and a 200 day simple moving average of $25.26. The stock has a market cap of $1.53 billion, a price-to-earnings ratio of -6.80 and a beta of 1.24.

Analysts Set New Price Targets

CLDX has been the subject of several recent analyst reports. Barclays boosted their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $41.56.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CLDX. Wilmington Savings Fund Society FSB bought a new position in shares of Celldex Therapeutics during the third quarter valued at about $42,000. Russell Investments Group Ltd. increased its position in Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the period. Quantbot Technologies LP bought a new position in Celldex Therapeutics in the 3rd quarter worth $63,000. Kestra Advisory Services LLC purchased a new position in shares of Celldex Therapeutics during the fourth quarter valued at about $98,000. Finally, Advisory Services Network LLC purchased a new stake in Celldex Therapeutics in the third quarter worth about $139,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.